Back
Peptide

CJC-1295 Research: GHRH Analogue Structure and Laboratory Studies

CJC-1295 Research Peptide Banner

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, commonly abbreviated as GHRH.

What makes the original CJC-1295 molecule scientifically distinctive is not simply its relationship to GHRH. Its defining feature is a reactive chemical modification designed to attach the peptide to serum albumin after administration.

This albumin-binding strategy dramatically changes the molecule’s persistence compared with ordinary GHRH fragments.

The original research form of CJC-1295 was developed from a modified human GHRH(1–29) backbone and incorporates a maleimide-containing group capable of forming a covalent bond with albumin. Early research identified CJC-1295 as a long-acting GHRH analogue that remained detectable in circulation far longer than unmodified GHRH fragments.

This makes CJC-1295 especially useful for research involving:

  • GHRH receptor signaling
  • Albumin conjugation
  • Long-acting peptide design
  • Peptide pharmacokinetics
  • Growth hormone secretory patterns
  • Protein-peptide bioconjugation
  • Analytical characterization

For research purposes only. Not for human or veterinary use.

What Is CJC-1295?

CJC-1295 is a synthetic peptide analogue based on the first 29 amino acids of human growth hormone-releasing hormone.

Natural GHRH is produced in the hypothalamus.

It signals primarily through the GHRH receptor, which is expressed on growth hormone-producing cells of the anterior pituitary.

CJC-1295 was engineered to retain GHRH receptor activity while resisting rapid clearance.

The original molecule contains several amino-acid substitutions and an additional reactive chemical group that enables binding to albumin.

This design distinguishes CJC-1295 from ordinary short-acting GHRH fragments.

Why GHRH(1–29) Is Important

Human GHRH is longer than 29 amino acids.

However, the first 29 residues contain the major receptor-active region.

This led researchers to study GHRH(1–29) as a shorter functional fragment.

The challenge was stability.

Short GHRH-derived peptides are rapidly degraded by enzymes, including dipeptidyl peptidase IV, also known as DPP-4.

Researchers therefore modified the peptide backbone to reduce enzymatic degradation.

CJC-1295 built on this concept by combining a stabilized GHRH analogue with an albumin-binding chemical system.

CJC-1295 Is a Modified GHRH Analogue

The peptide backbone used in CJC-1295 is not identical to native GHRH.

Several substitutions were introduced to improve stability and preserve receptor activity.

The research molecule was described as a tetrasubstituted form of hGRF(1–29) with an additional reactive lysine derivative at the C-terminal end.

This means researchers should distinguish between:

  • Native GHRH
  • Native GHRH(1–29)
  • Stabilized GHRH(1–29) analogues
  • CJC-1295 with its albumin-binding modification

They are related but chemically distinct research materials.

What Does DAC Mean?

CJC-1295 is often discussed together with the term DAC.

DAC stands for:

Drug Affinity Complex

In the original CJC-1295 design, the DAC concept refers to a reactive chemical group that allows the peptide to bind covalently to serum albumin.

This is the feature that gives the original CJC-1295 its unusually prolonged persistence.

The peptide therefore behaves differently from a conventional short GHRH analogue after entering a biological system.

Albumin Binding Is the Key Design Feature

Albumin is one of the most abundant proteins in plasma.

It circulates for a relatively long time.

Drug developers have used albumin binding as a strategy to extend the persistence of short-lived molecules.

CJC-1295 was specifically designed to exploit this property.

The reactive group on the peptide can bind to a free thiol group on albumin, particularly Cys34.

Once conjugated, the peptide effectively circulates as an albumin-associated bioconjugate.

The original development study showed CJC-1295-related immunoreactivity at the serum-albumin band after administration, supporting the intended conjugation mechanism.

Why Albumin Binding Extends Persistence

A small peptide can be cleared relatively quickly through:

  • Proteolytic degradation
  • Renal filtration
  • Cellular uptake
  • Metabolic processing

Albumin association changes this.

The much larger albumin-peptide conjugate is less susceptible to rapid renal clearance.

Albumin can also provide partial protection from some forms of peptide degradation.

This allows receptor-active peptide material to remain in circulation for a substantially longer period.

In human research, the estimated half-life of CJC-1295 was reported at approximately 5.8 to 8.1 days.

CJC-1295 and the GHRH Receptor

CJC-1295 retains activity at the GHRH receptor.

The GHRH receptor is a G protein-coupled receptor, or GPCR.

It is mainly associated with somatotroph cells in the anterior pituitary.

When GHRH or a suitable analogue activates the receptor, intracellular signaling can stimulate growth hormone release.

The original CJC-1295 development work demonstrated activity in cultured anterior pituitary cells and in animal models.

GHRH Receptor Signaling

The GHRH receptor primarily couples to Gs proteins.

Activation can stimulate:

adenylyl cyclase

which increases:

cyclic AMP, or cAMP

within the cell.

Higher intracellular cAMP can activate downstream protein kinase signaling and influence growth hormone synthesis and release.

Researchers studying CJC-1295 may therefore examine endpoints such as:

  • cAMP generation
  • Receptor activation
  • Growth hormone secretion
  • Signal duration
  • Receptor desensitization

Why cAMP Is Useful in Laboratory Research

cAMP provides a measurable intracellular signal.

Researchers can expose receptor-expressing cells to different concentrations of a GHRH analogue and measure the resulting cAMP response.

This can help estimate:

  • Potency
  • Maximum response
  • Concentration-response relationships
  • Receptor specificity

Comparing native GHRH with CJC-1295 can help isolate the effects of structural modification.

CJC-1295 Was Designed for Prolonged Stimulation

Natural GHRH signaling is short-lived.

CJC-1295 was designed to remain available for much longer periods.

This raises an important research question:

Does prolonged GHRH receptor stimulation eliminate normal growth hormone pulsatility?

Human research investigated this directly.

One study found that growth hormone secretion remained pulsatile one week after CJC-1295 administration, even though basal and mean GH concentrations increased.

This finding became important because it showed that prolonged GHRH stimulation did not simply produce completely continuous growth hormone release.

Growth Hormone Pulsatility

Growth hormone is normally secreted in pulses.

These pulses vary throughout the day.

Researchers studying long-acting GHRH analogues therefore need to evaluate both:

  • Total growth hormone exposure
  • Secretory pattern

CJC-1295 research found that pulse frequency and pulse magnitude remained generally preserved while baseline GH concentrations increased.

This demonstrates why analyzing only a single hormone concentration may provide incomplete information.

Why Pulsatility Matters Scientifically

Hormone signaling can depend on timing.

A pulsed signal may produce different downstream effects from constant exposure.

Researchers may therefore study:

  • Pulse frequency
  • Pulse amplitude
  • Baseline concentrations
  • Total secretion
  • Timing

CJC-1295 provides an interesting experimental model because it produces sustained GHRH receptor stimulation while allowing measurable GH pulsatility to persist.

IGF-1 Research

Growth hormone can influence production of insulin-like growth factor 1, commonly abbreviated IGF-1.

Human CJC-1295 studies therefore measured both GH and IGF-1.

Research reported that a single exposure increased GH for several days and increased IGF-1 for a longer period. The published clinical study reported an estimated CJC-1295 half-life of roughly 5.8–8.1 days.

These data were obtained under controlled experimental conditions.

They should not be interpreted as instructions for personal use.

Serum Proteomics Research

CJC-1295 has also been used as a research tool for examining downstream protein changes associated with GH and IGF-1 signaling.

One study analyzed serum samples from healthy adult men before and after CJC-1295 exposure using two-dimensional gel electrophoresis and mass spectrometry.

The researchers identified several protein spots that changed after activation of the GH/IGF-1 axis.

This illustrates how a GHRH analogue can be used as an experimental probe for broader endocrine signaling.

Why Proteomics Adds Another Layer

Measuring GH alone provides information about hormone release.

Measuring IGF-1 provides information about a downstream endocrine response.

Proteomics can examine wider changes in circulating proteins.

This can help researchers investigate:

  • Biomarkers
  • Downstream pathways
  • Protein-processing changes
  • System-wide responses

CJC-1295 therefore has relevance beyond simple receptor-binding experiments.

The Difference Between CJC-1295 and Tesamorelin

CJC-1295 and Tesamorelin are both related to GHRH.

However, they are not the same molecule.

Tesamorelin is a stabilized GHRH analogue with its own structural modification.

CJC-1295 was developed around a different concept:

albumin bioconjugation for prolonged exposure.

This changes the scientific focus.

Tesamorelin research frequently emphasizes GHRH analogue structure and receptor activity.

CJC-1295 research adds another layer involving:

  • Covalent albumin binding
  • Long-duration circulation
  • Protein bioconjugation
  • Extended pharmacokinetics

CJC-1295 and Ipamorelin Are Mechanistically Different

CJC-1295 should also be distinguished from Ipamorelin.

CJC-1295 is a GHRH receptor agonist.

Ipamorelin belongs to the growth hormone secretagogue family and signals primarily through the growth hormone secretagogue receptor, GHS-R1a.

Therefore, the two compounds act through different receptor systems.

This distinction is essential when discussing laboratory research.

GHRH and GHS-R Pathways

The GHRH receptor and GHS-R1a receptor can both influence growth hormone secretion.

However, they use different upstream signaling mechanisms.

GHRH receptor activation is strongly associated with:

  • Gs signaling
  • Adenylyl cyclase
  • cAMP

GHS-R1a signaling commonly involves:

  • Gq-related pathways
  • Phospholipase C
  • Intracellular calcium

This makes GHRH analogues and growth hormone secretagogues useful for comparative receptor research.

“CJC-1295 With DAC” and Naming Confusion

One of the biggest problems surrounding CJC-1295 is inconsistent naming.

Historically, the molecule described in the scientific literature as CJC-1295 already contains the albumin-binding modification.

In other words, the original CJC-1295 is the long-acting albumin-binding research compound.

The phrase:

CJC-1295 with DAC

is commonly used in commercial settings to emphasize this feature.

However, researchers should always verify the exact chemical structure rather than relying only on a product name.

What Is “CJC-1295 No DAC”?

The phrase CJC-1295 no DAC is widely used by research suppliers.

However, this naming can be misleading.

Products sold under this name are generally referring to Modified GRF(1–29), also called Mod GRF 1-29, rather than the original long-acting CJC-1295 molecule described in the published development literature.

The original peer-reviewed CJC-1295 research centers specifically on the albumin-binding analogue.

Researchers should therefore verify:

  • Exact sequence
  • Terminal modification
  • Presence or absence of the reactive albumin-binding group
  • Molecular mass

before assuming two products are chemically equivalent.

Why “No DAC” Is More Than a Small Difference

Removing the albumin-binding functionality changes the entire pharmacokinetic concept.

A peptide without the reactive group:

  • Does not form the same albumin conjugate
  • Has a much shorter persistence
  • Is cleared differently
  • Produces a different exposure profile

Therefore, researchers should not treat “CJC-1295 with DAC” and a short-acting Mod GRF-type analogue as interchangeable materials.

Modified GRF(1–29)

Modified GRF(1–29) is itself a useful GHRH research peptide.

It incorporates substitutions designed to improve stability relative to native GHRH(1–29).

However, without the albumin-binding chemistry, it remains fundamentally different from the original CJC-1295 design.

This distinction should remain clear in scientific writing.

Why Exact Chemical Identity Matters

Research product names are not always chemically precise.

The same marketing label may be used for materials with different:

  • Sequences
  • Terminal groups
  • Salt forms
  • Reactive modifications

For CJC-1295, this is especially important.

A laboratory should verify the actual molecule from:

  • Certificate of Analysis
  • Mass data
  • Sequence information
  • Supplier specification

rather than assuming the name alone is sufficient.

CJC-1295 Molecular Mass

Different databases may report different CJC-1295-related entries depending on whether they represent:

  • The long-acting DAC-containing compound
  • A modified GHRH backbone
  • A salt form

For example, PubChem entries associated with CJC-1295 report molecular masses in the several-kilodalton range, with values differing depending on the exact recorded structure.

This reinforces the importance of specifying the exact chemical species.

Albumin Conjugation Chemistry

The albumin-binding feature of CJC-1295 uses maleimide chemistry.

Maleimide groups are reactive toward thiol groups.

Albumin contains a free thiol at Cys34.

This creates an opportunity for selective covalent attachment.

Researchers studying the conjugation process may examine:

  • Reaction rate
  • Albumin occupancy
  • Conjugate stability
  • Free peptide
  • Conjugated peptide

This is one reason CJC-1295 is interesting from both peptide and protein chemistry perspectives.

Why Covalent Binding Is Different From Reversible Binding

Some long-acting peptides associate reversibly with albumin.

CJC-1295 was designed for covalent attachment.

That means the peptide-albumin complex forms a chemical bond rather than relying only on weak intermolecular attraction.

This creates a very different persistence mechanism.

Researchers should not assume all albumin-binding peptides use the same strategy.

Ex Vivo Albumin Conjugation Research

The original development study synthesized several maleimide-containing GHRH derivatives.

Researchers conjugated these compounds with human serum albumin and tested their stability and receptor activity.

The resulting albumin conjugates retained bioactivity and showed improved stability against DPP-IV.

This helped demonstrate that covalent attachment did not necessarily eliminate GHRH receptor activity.

DPP-IV Resistance

DPP-IV is important because it can rapidly inactivate certain peptides.

GHRH-derived peptides are particularly susceptible to cleavage near the N-terminus.

The CJC-1295 design included amino-acid substitutions intended to improve enzymatic stability.

Researchers can study this by comparing degradation of:

  • Native GHRH
  • GHRH(1–29)
  • Stabilized GRF analogues
  • CJC-1295

under controlled enzymatic conditions.

Why Amino-Acid Substitution Matters

One amino-acid change can strongly affect peptide degradation.

An enzyme recognizes both sequence and structure.

Changing a residue near a cleavage site may:

  • Reduce enzyme binding
  • Slow cleavage
  • Alter peptide conformation

This principle is common in peptide engineering.

CJC-1295 combines this strategy with albumin binding for an additional increase in persistence.

Structure-Activity Research

Researchers can use CJC-1295 as a model for studying how several molecular modifications work together.

Questions may include:

  • Which substitutions improve DPP-IV resistance?
  • Does the albumin conjugate retain receptor activity?
  • Does conjugation change potency?
  • How does signal duration change?
  • Does prolonged exposure alter receptor responsiveness?

These experiments provide insight into long-acting peptide design.

Receptor Desensitization

Long-duration receptor stimulation raises another question:

Does the receptor become less responsive over time?

GPCRs can undergo:

  • Phosphorylation
  • Internalization
  • Desensitization
  • Recycling

Researchers studying prolonged GHRH receptor stimulation may examine whether CJC-1295 changes receptor responsiveness after extended exposure.

This area is important because long persistence does not automatically mean constant receptor activity.

Why Human Pulsatility Data Are Interesting

The observation that GH pulsatility remained detectable during prolonged CJC-1295 stimulation suggests that downstream endocrine control mechanisms remain active despite sustained GHRH receptor exposure.

This provides an interesting model for studying how:

  • Continuous upstream stimulation
  • Pulsatile downstream secretion

can coexist.

Animal Research

Before human studies, CJC-1295 was evaluated in animals.

Research examined:

  • GH release
  • Plasma persistence
  • Albumin conjugation
  • Growth-related endpoints

The initial development paper reported prolonged circulation and enhanced GH exposure in rats compared with ordinary hGRF(1–29).

Animal results helped establish the biological plausibility of the albumin-binding design.

Human Research

CJC-1295 later entered controlled human studies.

One study reported prolonged increases in GH and IGF-1 after administration, with a calculated half-life lasting several days.

Another study examined GH secretory pulsatility one week after exposure.

These studies are part of the compound’s research history.

They do not mean research-grade CJC-1295 products are approved medicines.

CJC-1295 Is Not an Approved General-Use Drug

Research material should remain clearly separated from regulated pharmaceutical products.

CJC-1295 has been studied experimentally, but a research vial should not be represented as an approved therapeutic formulation.

Researchers should distinguish:

  • Published experimental compound
  • Laboratory research material
  • Approved pharmaceutical products

These categories are not interchangeable.

Analytical Identification of CJC-1295

CJC-1295 requires careful analytical characterization because it contains more than a simple peptide backbone.

Researchers may need to confirm:

  • Amino-acid sequence
  • Molecular mass
  • Terminal modifications
  • DAC-related group
  • Purity
  • Salt form

A generic “GHRH analogue” label is not enough.

HPLC Characterization

High-performance liquid chromatography can help evaluate sample composition.

Researchers may examine:

  • Main peak
  • Retention time
  • Minor peaks
  • Relative peak area
  • Batch consistency

However, HPLC alone cannot prove the exact albumin-binding structure.

A highly pure incorrect analogue could still produce a dominant chromatographic peak.

Mass Spectrometry

Mass spectrometry can help verify molecular identity.

Researchers may compare observed mass with the expected mass of the intended CJC-1295 species.

Mass analysis may detect:

  • Truncated products
  • Incorrect modifications
  • Synthesis-related impurities
  • Degradation products

This is particularly important when distinguishing CJC-1295 from related GRF analogues.

Why Sequence Alone Is Not Enough

Two materials may share the same basic GHRH-derived peptide sequence while differing in terminal chemistry.

If one contains the albumin-binding group and the other does not, they are not analytically equivalent.

Therefore, laboratories should verify:

  • Peptide backbone
  • Reactive modification
  • Terminal structure

before describing a sample as CJC-1295.

Albumin-Binding Assays

Researchers interested in DAC function can directly examine conjugation.

Possible methods may include:

  • Protein gel analysis
  • Mass spectrometry
  • Albumin-binding assays
  • Size-based separation

The original development study used Western blot analysis to show CJC-1295-associated signal corresponding to serum albumin after administration.

This provides a useful benchmark for understanding how the molecule was originally characterized.

Free Peptide vs Albumin-Bound Peptide

After exposure to albumin, a sample may contain both:

  • Unbound CJC-1295
  • Albumin-conjugated CJC-1295

These forms differ substantially in size.

Researchers studying pharmacokinetics or receptor exposure should account for this distinction.

Total peptide measurement alone may not reveal how much is conjugated.

Stability Research

CJC-1295 stability can be influenced by:

  • Temperature
  • pH
  • Moisture
  • Oxidation
  • Storage duration
  • Reactive-group integrity

The maleimide-containing component deserves particular attention because reactive chemical groups can undergo side reactions or hydrolysis.

This makes storage and handling especially relevant for analytical research.

Why Reactive-Group Integrity Matters

The albumin-binding concept depends on a functional reactive group.

If that group changes chemically during storage, the sample may retain its peptide sequence but lose its intended conjugation behavior.

A stability program may therefore need to examine both:

  • Peptide integrity
  • DAC reactivity

This is different from studying an ordinary unmodified peptide.

Batch Traceability

A research laboratory should record:

  • Product name
  • Exact chemical form
  • Batch number
  • Sequence
  • Modification information
  • Purity result
  • Identity test
  • Storage history

This is especially important because of commercial naming confusion around CJC-1295.

Certificate of Analysis Review

A useful COA should make clear which compound was actually tested.

Researchers should look for:

  • Molecular identity
  • Expected molecular mass
  • HPLC data
  • Mass spectrometry
  • Batch number
  • Testing date

If a product is labeled “CJC-1295,” the analytical data should support the exact stated form.

CJC-1295 vs “CJC-1295 No DAC” in Laboratory Records

Researchers should avoid combining results from these materials under one label.

Instead, documentation should specify:

CJC-1295 with albumin-binding DAC structure

or

Modified GRF(1–29) / short-acting non-DAC analogue

depending on the actual material.

This improves reproducibility and reduces ambiguity.

Why Nomenclature Can Affect Research Quality

If two laboratories use different molecules but both call them “CJC-1295,” their results may appear contradictory.

The real problem may simply be material identity.

Clear nomenclature can prevent:

  • Incorrect comparisons
  • Misinterpreted pharmacokinetics
  • Conflicting receptor data
  • Reproducibility problems

This is one of the most important practical lessons from CJC-1295 research.

Experimental Controls

A CJC-1295 laboratory study may include:

  • Native GHRH
  • GHRH(1–29)
  • Modified GRF(1–29)
  • CJC-1295
  • Albumin-conjugated CJC-1295
  • Vehicle control

This design allows researchers to separate the effects of:

  • Backbone modification
  • Enzymatic stabilization
  • Albumin binding

Concentration-Response Studies

For receptor research, several concentrations should usually be tested.

Researchers may calculate:

  • EC50
  • Maximum response
  • Signal duration
  • Receptor occupancy

Comparing free and albumin-bound forms can provide additional information about how conjugation affects receptor access.

Time-Course Studies

Time is particularly important for CJC-1295.

Researchers may evaluate:

  • Immediate receptor response
  • Short-term GH release
  • Extended exposure
  • Delayed IGF-1 changes

The defining feature of the compound is its prolonged behavior, so single-time-point studies may miss important information.

Why CJC-1295 Is Useful in Peptide Engineering Research

CJC-1295 illustrates several major strategies used in modern peptide design:

  1. Identify the minimum receptor-active peptide region.
  2. Modify vulnerable amino acids.
  3. Improve resistance to enzymatic degradation.
  4. Add a pharmacokinetic extension system.
  5. Verify that receptor activity remains intact.

This makes CJC-1295 useful as a model far beyond GHRH biology alone.

Albumin Conjugation as a Broader Research Strategy

Albumin is frequently used in drug-delivery research.

Scientists may design compounds that bind albumin through:

  • Covalent chemistry
  • Fatty-acid binding
  • Albumin-binding domains
  • Antibody fragments

CJC-1295 represents the covalent bioconjugation approach.

This distinguishes it from lipidated peptides such as semaglutide, which interact with albumin through a different mechanism.

CJC-1295 vs Semaglutide Albumin Interaction

Both CJC-1295 and semaglutide use albumin-related strategies to increase persistence.

However, the chemistry is different.

Semaglutide contains a fatty-acid side chain that promotes reversible albumin association.

CJC-1295 uses a reactive group designed for covalent albumin conjugation.

This comparison illustrates how different molecular engineering strategies can target the same pharmacokinetic problem.

Evidence Limitations

Although CJC-1295 has published animal and human research, the evidence base is relatively limited compared with extensively developed pharmaceutical compounds.

Researchers should distinguish:

  • Early development studies
  • Small human studies
  • Mechanistic research
  • Established clinical evidence

The presence of human experimental data does not justify treating a research compound as a routine clinical product.

Avoiding Unsupported Claims

Responsible CJC-1295 content should focus on documented research findings.

Appropriate topics include:

  • GHRH receptor activation
  • Albumin conjugation
  • GH pulsatility
  • Pharmacokinetics
  • Analytical chemistry

Claims about personal outcomes, performance, or treatment should not be inferred from laboratory findings.

CJC-1295 Research and Bayoupep USA

At Bayoupep USA, CJC-1295-related material should be treated strictly as laboratory research material.

Researchers should verify:

  • Exact peptide sequence
  • Presence or absence of DAC chemistry
  • Molecular mass
  • Batch-specific analytical identity
  • Purity
  • Storage information

Because the term CJC-1295 is used inconsistently across the research-product market, confirming the exact chemical form is especially important.

For research purposes only. Not for human or veterinary use.

Final Thoughts

CJC-1295 is an important example of how peptide engineering can change the behavior of a naturally short-lived signaling molecule.

The original research compound combines:

  • A stabilized GHRH(1–29)-derived backbone
  • Amino-acid substitutions intended to resist degradation
  • A reactive albumin-binding modification
  • Long-duration exposure

The albumin-conjugation strategy is the defining feature.

Early development studies demonstrated formation of albumin-associated CJC-1295 and prolonged circulation, while subsequent human research reported an estimated half-life of approximately 5.8–8.1 days.

Research also found that growth hormone secretion remained pulsatile despite prolonged GHRH stimulation.

From a laboratory perspective, CJC-1295 therefore offers a useful model for studying:

  • GHRH receptor biology
  • GPCR signaling
  • Peptide stabilization
  • Covalent protein conjugation
  • Endocrine pulsatility
  • Long-acting peptide design

One of the most important practical issues is nomenclature.

The original CJC-1295 described in scientific literature is the albumin-binding long-acting molecule. Products marketed as “CJC-1295 no DAC” usually refer to a related short-acting Modified GRF(1–29)-type analogue rather than the same pharmacokinetic entity.

For meaningful research, molecular identity should always take priority over the product nickname.

Accurate sequence documentation, verification of the albumin-binding modification, mass spectrometry, chromatography, batch traceability, and careful interpretation of experimental evidence are essential.

This information is provided for scientific and educational research purposes only. CJC-1295 research materials are not intended for human or veterinary use.

 

 

Keep reading

Related articles

All articles →

1 comment

Leave a comment

Your email address is never published. Required fields are marked *